the icgeb mandate: to provide ahttpassets... · crps awarded/year amount awarded/ye ar c r p s a w...
TRANSCRIPT
80+ Signatory States, 60+ Member States
3 Components: Trieste (Italy) – New Delhi (India) - CapeTown (South Africa)
a network of 40+ Affiliated Centres
Developing knowledge
International
Centre for
Genetic
Engineering and
Biotechnology
Trieste New Delhi
Cape
Town
ICGEBThe ICGEB Mandate: to provide a Centre of excellence for research, training and technology transfer to industry in the field of biotechnology, to promote sustainable global development
ICGEBACTION
• Cutting-edge scientific research in its laboratories in Trieste, New Delhi
and Cape Town
• Advanced training supported by long- and short-term fellowships for PhD
students and post-docs
• Organisation of Meetings, Courses and Workshops at the international
level
• Competitive research grants for scientists in Member Countries, including
Early Career Return Grants
• Technology transfer to industry for the production of biotherapeutics and
diagnostics
ICGEB research
Patents
- Dengue subunit vaccine quadrivalent
candidate DSV against all four DENV
serotypes (PCT/IB2015/056352 – Khanna N.
et al.)
- Anti dengue activity of Cissampelos pariera
extracts (PCT/IB2010/050299 - Bhatnager,
P.K. et al.)
Infection of rice
Cardiovascular disorders
regeneration, gene therapy, miRNA
Infectious diseases
Malaria, HIV, Dengue, TB, Trypanosomiasis, Leishmanioisis, Toxoplasmosis, crop diseases, vectors’ biology
CancerHPV, angiogenesis, cancer genetics/genomics
NeurodegenerationALS, dementia, Alzheimer, Parkinson
Genetic diseasesGene therapy, splicing correction, immunodeficiencies
Plant biologycrop improvement, stress resistance, bio-inoculants
EnvironmentBioremediation
Energy\
• Cutting-edge scientific research in its laboratories in Trieste, New Delhi
and Cape Town
• Advanced training supported by long- and short-term fellowships for PhD
students and post-docs
• Organisation of Meetings, Courses and Workshops at the international
level
• Competitive research grants for scientists in Member Countries, including
Early Career Return Grants
• Technology transfer to industry for the production of biotherapeutics and
diagnostics
ICGEBACTION
The Arturo Falaschi ICGEB Fellowship
Program offers long and short-term fellowships
for scientists from ICGEB Member States to
perform research in Trieste, New Delhi or Cape
Town.
ICGEB PhD: aim at the Doctor Philosophiae
(PhD) degree in the life sciences. The title is
awarded through a number of academic
institutions of international standing: The Open
University (UK), the International School for
Advanced Studies (SISSA) in Trieste, the
Jawaharlal Nehru University in New Delhi and the
University of Cape Town in South Africa.
ICGEB postdoc: to highly motivated scientists
wishing to pursue postdoctoral research in ICGEB
laboratories.
Short-term fellowships: for Pre-doctoral and
Postdoctoral studies in ICGEB laboratories to fund
ongoing collaborative research between scientists
from ICGEB Member States and research groups
at ICGEB, with the aim of facilitating access to the
latest research techniques and to strengthen
capacity building.
Scientific Mobility for Advanced Research
Training (SMART): to promote the mobility of
researchers between ICGEB Member States (i.e.
South-South cooperation).
ICGEB: Training
• Cutting-edge scientific research in its laboratories in Trieste, New Delhi
and Cape Town
• Advanced training supported by long- and short-term fellowships for PhD
students and post-docs
• Organisation of Meetings, Courses and Workshops at the international
level
• Competitive research grants for scientists in Member Countries, including
Early Career Return Grants
• Technology transfer to industry for the production of biotherapeutics and
diagnostics
ICGEBACTION
ICGEB Meeting: organized at the ICGEB Components,
250-300 participants, invited speakers and selected oral
presentations, poster sessions, registration fee.
ICGEB Workshop: organized in Member States, 80-120
participants from laboratories working on a focused topic, oral
and poster sessions.
ICGEB Course: theoretical and/or practical, 25-50
participants and 5-10 instructors.
ICGEB & The Future of Science: 1-2 days,
involving 2-6 high profile leaders in the field. May involve
working groups on current hot topics of particular public
relevance and/or examine in a public context novel scientific
developments that will impact on our society, with open
communication to media and the general public.
Sponsorship of other meetings: financial
contribution towards a scientific meeting organized in a
Member State on a topic of relevance to the ICGEB mandate.
ICGEB Meetings & Courses
LATIN AMERICA (139)
ARGENTINA: 47
BRAZIL: 14
CHILE: 4
COLOMBIA: 6
COSTA RICA: 11
CUBA: 7
MEXICO: 18
PANAMA: 3
PERU: 11
URUGUAY: 7
VENEZUELA: 7
NICARAGUA: 4
EUROPE (55)
CROATIA: 1
ITALY: 18
POLAND: 6
SERBIA: 1
SLOVENIA: 2
AUSTRIA: 2
BELGIUM: 2
CZECH REP.: 2
FINLAND: 2
FRANCE: 9
GERMANY: 1
GREECE: 2
SPAIN: 1
SWEDEN: 1
UK: 5
NORTH AMERICA (21)
CANADA: 2
USA: 19
AFRICA (14)
EGYPT: 7
NIGERIA: 2
SUDAN: 3
TUNISIA: 2
ASIA (69)
CHINA: 1
INDIA: 45
IRAN: 3
IRAQ: 1
PAKISTAN: 3
RUSSIAN FED.: 2
SRI LANKA: 2
SYRIAN ARAB REP.: 1
THAILAND: 1
TURKEY: 10
JAPAN: 4
KOREA: 1
***
*
*
Participants to RNAvirus@ICGEB
*Costa Rica 2016
Argentina 2012
Italy 2008
India 2010
China 2018
Turkey 2014
• Cutting-edge scientific research in its laboratories in Trieste, New Delhi
and Cape Town
• Advanced training supported by long- and short-term fellowships for PhD
students and post-docs
• Organisation of Meetings, Courses and Workshops at the international
level
• Competitive research grants for scientists in Member Countries, including
Early Career Return Grants
• Technology transfer to industry for the production of biotherapeutics and
diagnostics
ICGEBACTION
CRP - ICGEB Research Grants
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2013
2014
2015
2016
0
500,000
1,000,000
1,500,000
0
10
20
30A
mo
un
t a
wa
rde
d (€
)
Amount awarded/yearCRPs awarded/yearC
RP
s a
wa
rde
d/y
ea
r
> 460 grants~19 million Euro
over 1800 applications evaluated
Funds allocated 2015: 732 k€Average per grant: 45.8 k€
Basic Science
Human Healthcare
Industry &
Environment
Plant Science & Agriculture
REFERENCES
Baba, M et al. Virological point-of-care testing for the developing world. Future Virology,
9(6), 595-603 (2014).
Baba, M et al. Evidence of arbovirus co-infection in suspected febrile malaria and
typhoid patients in Nigeria. J Infect Dev Ctries 7, 51-9 (2013).
Baba, M et al. A survey for neutralizing antibodies to the three types of poliovirus
among children in Maiduguri, Nigeria. J Med Virol 84, 691-6 (2012).
ICGEB CRP NGA16_010
Establishment of a reference laboratory for Arbovirus infection
surveillance at the WHO/ITD Laboratory, University of Maiduguri
Teaching Hospital, Borno State, NIGERIA (Head: Professor Marycelin
M. Baba)ACHIEVEMENTS
- Implementation of virological assays (IgM/IgG ELISA, RT-PCR, PRNT);
- Exchange of knowhow and researchers;
- Survey of Arbovirus sero-prevalence in 310 suspected febrile Malaria
and Typhoid patients in Nigeria;
• Cutting-edge scientific research in its laboratories in Trieste, New Delhi
and Cape Town
• Advanced training supported by long- and short-term fellowships for PhD
students and post-docs
• Organisation of Meetings, Courses and Workshops at the international
level
• Competitive research grants for scientists in Member Countries, including
Early Career Return Grants
• Technology transfer to industry for the production of biotherapeutics and
diagnostics
ICGEBACTION
Biotechnology transfer The transfer of technologies is one of the most relevant activities of ICGEB. Over 70
agreements have been concluded with industrial partners located in Argentina, Brazil,
China, Cuba, Egypt, India, Iran, Pakistan, Russia, South Africa, Sri Lanka, Syria,
Turkey, United Arab Emirates, United States of America, Uruguay and Venezuela.
The procedure to transfer ICGEB technologies foresees the finalization of a
Technology Transfer Agreement, which usually provides for a period of training in the
ICGEB laboratories by a number of industrial partners' employees, a supply of
genetically modified strains and the protocols for the production, purification and quality
control of a specific biotechnological product.
ProductsRecombinant Human Erythropoietin
Recombinant Human Interferon α2a
Recombinant Granulocyte Colony Stimulating Factor
Recombinant Human Insulin
Recombinant Human β Interferon 1B
Recombinant Pegylated Human Interferon α2a
Recombinant Pegylated Granulocyte Colony Stimulating Factor
Recombinant Hepatitis B Surface Antigen (R-HBsAg)
Thank you Alessandro Marcello
Head, Molecular
Virology
+39 040 3757384
http://www.icgeb.org